Some operational headwinds have GMP Securities analyst Martin Landry lowering his price target on MedReleaf (MedReleaf Stock Quote, Chart, News: … [Read more...] about GMP lowers price target on MedReleaf
Your company can reach thousands of cannabis sector investors by becoming the exclusive annual sponsor of this section. Contact us for details.
Mixed first quarter results have Echelon Wealth Partners analyst Russell Stanley trimming his price target on Canopy Growth Corp. (Canopy Growth Corp. … [Read more...] about Canopy Growth Corp gets price target cut at Echelon Wealth
Canaccord Genuity analyst Matt Bottomley thinks the latest deal from Aphria (Aphria Stock Quote, Chart, News: TSX:APH) allows it to capitalize on its … [Read more...] about Aphria deal with Nuuvera gets thumbs-up at Canaccord Genuity
The exit of CFO Jeremy Blumer took him a little off-guard, but Canaccord Genuity analyst Neil Maruoka thinks Maricann Group (Maricann Group Stock … [Read more...] about Maricann Group is a buy despite CFO departure: Canaccord Genuity
What he describes as "superior" products is just one of the reasons PI Financial analyst Jason Zandberg thinks Aurora Cannabis (TSX:ACB) is a buy … [Read more...] about Aurora Cannabis has the most potent strains of marijuana, PI says
A large inventory write-off for OrganiGram (OrganiGram Stock Quote, Chart, News: TSXV:OGI) is shaking GMP Securities analyst Martin Landry's faith in … [Read more...] about OrganiGram is still undervalued, GMP says
A leader in California’s burgeoning marijuana industry says that due to state regulations coming into play next year, pot growers will be banned from … [Read more...] about California’s pot growers are on a “painful downsizing curve,” says industry head
Filing delays for Canadian Bioceutical (Canadian Bioceutical Stock Quote, Chart, News: CSE:BCC) won't be a long-term problem, says Echelon Wealth … [Read more...] about Canadian Bioceutical’s delays will be short lived, Echelon says
The only Licensed Producer in Quebec is a buy right now, says Canaccord Genuity analyst Matt Bottomley. In a research report to clients today, … [Read more...] about The Hydropothecary Corporation is undervalued, says Canaccord Genuity
Canadian marijuana stocks have taken a tumble of late, but as we move closer to next year’s legalization of recreational cannabis, … [Read more...] about Is Canada’s pot sector all dried up?